Haematological cancer: Pembrolizumab is effective in multiple myeloma.
Sidaway P. Nat Rev Clin Oncol. 2017 May 23. doi: 10.1038/nrclinonc.2017.76. [Epub ahead of print].

A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractorymultiple myeloma.
Martin T et al. Blood. 2017 May 8. pii: blood-2016-09-740787. doi: 10.1182/blood-2016-09-740787. [Epub ahead of print].

Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma.
Badros A et al. Blood. 2017 May 1. pii: blood-2017-03-775122. doi: 10.1182/blood-2017-03-775122. [Epub ahead of print].